Cinclus: Q2 reiterated phase 3 trial timeline
Cinclus Pharma reported its Q2'24 results with a cash position at SEK 684.72m and an EBIT at SEK (37.329m). On the operations side, it has been reiterated that i) the company is looking to enroll the first patient in the 1st phase 3 study in 2025, with a readout expected in 2026, and ii) its Chines
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.